AUG 7, 2026 · PHASE 3 TRIAL
Pembrolizumab With or Without Maintenance Sacituzumab Tirumotecan (Sac-TMT; MK-2870) in Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) [MK-2870-023]
ClinicalTrials.gov
This is a clinical trial registry record describing a planned Phase 3 study with no results posted; the record documents study design and hypothesis only, not clinical outcomes.
Reported
PhasePhase 3
Planned enrollment851
Primary outcome measureOverall survival (OS), up to ~50 months